Ebola Laboratory Response at the Eternal Love Winning Africa Campus, Monrovia, Liberia, 2014–2015

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

West Africa experienced the first epidemic of Ebola virus infection, with by far the greatest number of cases in Guinea, Sierra Leone, and Liberia. The unprecedented epidemic triggered an unparalleled response, including the deployment of multiple Ebola treatment units and mobile/field diagnostic laboratories. The National Institute of Allergy and Infectious Diseases and the Centers for Disease Control and Prevention deployed a joint laboratory to Monrovia, Liberia, in August 2014 to support the newly founded Ebola treatment unit at the Eternal Love Winning Africa (ELWA) campus. The laboratory operated initially out of a tent structure but quickly moved into a fixed-wall building owing to severe weather conditions, the need for increased security, and the high sample volume. Until May 2015, when the laboratory closed, the site handled close to 6000 clinical specimens for Ebola virus diagnosis and supported the medical staff in case patient management. Laboratory operation and safety, as well as Ebola virus diagnostic assays, are described and discussed; in addition, lessons learned for future deployments are reviewed.

Related collections

Author and article information

Journal

Journal ID (nlm-ta): J Infect Dis

Journal ID (iso-abbrev): J. Infect. Dis

Journal ID (publisher-id): jid

Journal ID (hwp): jinfdis

Title: The Journal of Infectious Diseases

Publisher: Oxford University Press

ISSN (Print): 0022-1899

ISSN (Electronic): 1537-6613

Publication date (Print): 15 October 2016

Publication date (Electronic): 04 October 2016

Publication date PMC-release: 15 October 2017

Volume: 214

Issue: Suppl 3 , Ebola Outbreak in West Africa

Pages: S169-S176

Affiliations

[1 ] Laboratory of Virology

[2 ] Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Hamilton, Montana

[3 ] Centers for Disease Control and Prevention , Atlanta, Georgia

[4 ] Cytokine Biology Section, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland

[5 ] Center for Global Health, Division of Global Health Protection, Centers for Disease Control and Prevention

[6 ] Kenya Medical Research Institute, Center for Global Health Research , Nairobi

[7 ] Special Pathogens Program, Public Health Agency of Canada , Winnipeg

[8 ] Ministry of Health and Social Welfare , Monrovia

[9 ] Liberian Institute for Biomedical Research , Charlesville, Liberia

Author notes

[a]

Present affiliations: Vaccine and Infectious Disease Organization, International Vaccine Center, University of Saskatchewan, Saskatoon, Canada (D. F.), and Public Health Agency of Canada, Winnipeg (D. S.); and Friedrich-Löffler-Institut, Greifswald–Insel Riems, Germany (A. G. and T. H.).

Correspondence: H. Feldmann, Laboratory of Virology, DIR, NIAID, NIH, 903 S 4th St, Hamilton, MT 59840 ( feldmannh@ 123456niaid.nih.gov ).

Article

Accession ID: PMC5050467 Pmcid ID: PMC5050467 Pmc-uid ID: 5050467 Publisher ID: jiw216

DOI: 10.1093/infdis/jiw216

PMC ID: 5050467

PubMed ID: 27333914

SO-VID: 90ee0b22-97b3-40b5-b790-5a8fdc5e424c

History

Funding

Funded by: National Institute of Allergy and Infectious Diseases [NIAID];

Funded by: National Institutes of Health;

Funded by: NIH;

Funded by: Intramural Research Program;

Funded by: NIAID;

Funded by: NIH;

Funded by: CDC;

Comments

Comment on this article

scite_

Cited by 11

See all cited by

- Version 1